Organisation paid for research Program year 2025 Source: CMS Open Payments

Dunes Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$1,207,243

51 payments

Through program year 2025, Dunes Clinical Research LLC is reported as receiving $1,207,243 in research payments, across 51 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $486,563 14
2024 Research $549,225 27
2023 Research $159,526 8
2022 Research $11,928 2

Breakdown

Who paid Research payments · program years 2022–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $621,046 6 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $247,567 23 payments
  3. AstraZeneca Pharmaceuticals LP $179,120 4 payments
  4. Amgen Inc. $72,264 2 payments
  5. Aurinia Pharma U.S., Inc. $61,245 14 payments
  6. Sanofi US Services Inc. $26,000 2 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $214,850 2 payments
  2. BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes $209,945 19 payments
  3. A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $198,790 1 payment
  4. A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK) $148,556 2 payments
  5. A Phase2b, Multicenter, Open-Label, Single-Arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies in Adolescents and Adults With Immunoglobulin A Nephropathy $130,153 1 payment
  6. A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis $72,264 2 payments
  7. LUPKYNIS Registry Study $49,318 12 payments
  8. A Phase 2/3, Multicenter, Open-Label Trial to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy $48,154 1 payment
  9. Epidemiology of Igan in the US and Its Associated Burden-Site-Based Census and Focus Phase $29,100 1 payment
  10. BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic $20,600 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record